Autopsy report · NCT05879458

Ritlecitinib in CTCL

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“No significant improvement in disease as graded by our assessments.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 2 years 1 month before it stopped.
7 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Icahn School of Medicine at Mount Sinai
Sponsor type: University, hospital or other
Conditions: CTCL; Mycosis Fungoides; Sezary Syndrome
Interventions: Ritlecitinib
Participants: 7
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.